The experience of colleagues physicians in application of phago-products will help to choose the optimal prevention and treatment regimen for a particular infectious disease
Treatment of cystitis with bacteriophages is advisable for both acute and chronic forms of the disease, especially when traditional uroantiseptics and antibiotics are ineffective. Common pathogens of infectious cystitis are destroyed by bacteriophages, wh
Representatives of opportunistic human flora often demonstrate multiple resistance to antibiotics. The use of bacteriophages in the treatment of purulent-inflammatory diseases of the ear, nose and throat allows not only to eliminate the infection, but als
When treating stomatitis, it is important to ensure disinfection of the oral cavity, eliminate pain and inflammation, and prevent the spread of infection. For the prevention and treatment of stomatitis, bacteriophage preparations are used, in particular t
Antibiotics for intestinal infections are prescribed only in the most severe cases. Most often, so-called intestinal antiseptics are used - drugs that act only in the intestinal lumen and are not always effective. An alternative to traditional antibacteri
For the prevention and treatment of purulent septic complications of wound processes, bacteriophages are used, in particular the drug Pyofag®. The drug has a bactericidal effect against a number of common pathogens, including antibiotic-resistant ones.
To eliminate opportunistic microflora, it is advisable to use appropriate bacteriophages. Phage preparations are highly specific - they destroy only certain bacteria without affecting beneficial microflora.
Register to receive additional information about phage therapy and phage preparations. Be sure to include your phone number so that we can contact you. Later, registered users will have access to the materials in the "For specialists" section, as well as an electronic newsletter and invitations to specialized events
Don't worry: Your personal data are safe
Phage therapy - is a field of medical microbiology, which is now actively developing and is the subject of numerous scientific and clinical studies, the "hot topic" of medical forums and congresses.
In a new study of a Pseudomonas aeruginosa wound infection model, scientists have shown that the effectiveness of phage therapy depends not only on the dose, but also on the delivery method and the duration of the phage's presence at the site of infection.
On September 21, 2026, Nature Medicine published the first detailed international consensus guideline on personalized phage therapy. Twenty professional societies, patient organizations, regulatory agencies, and 18 international experts contributed to its development. The document contains over 60 recommendations, ranging from the discovery and validation of a phage active against a specific bacterial strain to its production, quality control, administration, monitoring, and documentation of results.
Researchers isolated six new lytic bacteriophages from hospital wastewater capable of infecting multidrug-resistant E. coli strains. All phages rapidly attached to the bacteria, actively replicated, and achieved high titers—up to 10¹² PFU/ml. Genomic analysis revealed no known genes for antibiotic resistance, virulence, or lysogeny. Furthermore, all six phages demonstrated activity against established E. coli biofilms.
